Program
dazodalibep
Also written as “VIB4920”, “Dazodalibep” and “Inebilzumab+VIB4920”.
Its studies are mostly in Sjogren's Syndrome · Arthritis, Rheumatoid, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 82 open or running | phase 3since Oct 23, 2023 | May 3, 2016 | Dec 11, 2029phase 3 · NCT06747949 |
| AstraZeneca | 10 open or running | phase 1since May 27, 2014 | May 27, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 27, 2014First study: phase 1 study in Healthy VolunteerNew to AstraZenecaAstraZeneca · NCT02151110 · 59 enrolled · United Kingdom
- May 3, 2016Amgen's first study: phase 1 study in Arthritis, RheumatoidNew to AmgenAmgen · NCT02780388 · 57 enrolled · United States, Poland
- Aug 2, 2019Phase 2 study in Rejection, PsychologyAmgen · NCT04046549 · 25 enrolled · United States
- Oct 2, 2019Phase 2 study in Sjogren's SyndromeAmgen · NCT04129164 · 183 enrolled · United States, Argentina, France and more
- Nov 5, 20192 phase 2 studiesAmgen · NCT04174677, NCT04163991
- Oct 23, 2023Phase 3 study in Sjogren's SyndromeAmgen · NCT06104124 · 651 enrolled · United States, Argentina, Australia and more
- Jan 30, 2024Phase 3 study in Sjogren's SyndromeAmgen · NCT06245408 · 434 enrolled · United States, Argentina, Australia and more
- Dec 19, 2024Phase 3 study in Sjogren's SyndromeAmgen · NCT06747949 · 844 planned · United States, Argentina, Australia and more
Ahead
- Dec 11, 2029Primary completion: phase 3 study in Sjogren's SyndromeAmgen · NCT06747949
TargetBeta
“CD40 ligand antagonist”ChEMBL 37, by rule
Other programs on CD40LG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| frexalimab | Sanofi | phase 3 | 11 |
| dapirolizumab pegolrule | UCB | phase 3 | 8 |
| tegoprubartrule | eledon-pharmaceuticals | phase 3 | 8 |
| ravagalimabrule | AbbVie | phase 2 | 4 |
| OPT101rule | op-t-llc | phase 2 | 4 |
| TNX-1500rule | Tonix Pharmaceuticals | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06747949Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Recruiting | Amgen | Dec 11, 2029 | 844 |
| NCT06245408Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Amgen | Oct 22, 2026 | 434 |
| NCT06104124Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Completed | Amgen | Jul 23, 2026 | 651 |
| NCT04163991Arthritis, Rheumatoid · United States, Poland | 2 | Completed | Amgen | Dec 28, 2021 | 78 |
| NCT04174677Highly Sensitized Patients on Waiting List for Kidney Transplantation · United States | 2 | Withdrawn | Amgen | Dec 2021 | 0 |
| NCT04129164Sjogren's Syndrome · United States, Argentina, France and more | 2 | Completed | Amgen | Sep 1, 2022 | 183 |
| NCT04046549Rejection, Psychology · United States | 2 | Completed | Amgen | Jul 18, 2022 | 25 |
| NCT02780388Arthritis, Rheumatoid · United States, Poland | 1 | Completed | Amgen | May 21, 2018 | 57 |
| NCT02151110Healthy Volunteer · United Kingdom | 1 | Completed | AstraZeneca | May 9, 2016 | 59 |
How it is read
Names in the registry
- “VIB4920”, 5 entries
- “Dazodalibep”, 3 entries
- “Inebilzumab+VIB4920”, 1 entry
- “MEDI4920 3 mg”, 1 entry
- “MEDI4920 10 mg”, 1 entry
Codes read as this program: VIB4920.
Conditions, from the studies’ own filings
- Sjogren's Syndrome, 4 studies
- Arthritis, Rheumatoid, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.